All In Biotech

Drug Trial Radar · NCT05415215

A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer

A Phase IIIB, Multinational, Multicenter, Randomized, Open-Label Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer

Last checked: Nov 20, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 346 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

346

Actual

Start

Jul 5, 2022

Primary completion

Nov 20, 2024

Study completion Nov 7, 2025

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jun 13, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase IIIb, multinational, multicenter, randomized, open-label study to evaluate patient preference of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous use (PH FDC SC) administration in the home setting compared with the hospital setting during the cross-over period of adjuvant treatment in participants with early or locally advanced/inflammatory human epidermal growth factor receptor 2-positive (HER2+) breast cancer.

Conditions

  • Early Breast Cancer
  • Locally Advanced Breast Cancer
  • Inflammatory Breast Cancer

Interventions

  • Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)Drug

    PH FDC SC is administered subcutaneously (SC) as a fixed non-weight-based dose. A loading dose of 1200 milligram (mg) pertuzumab, 600 mg trastuzumab, and 30,000 units of recombinant human PH20 hyaluronidase (rHuPH20) is given in the first cycle (1 cycle is 21 days). In subsequent cycles, maintenance doses of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units rHuPH20 are administered once every 3 weeks (Q3W).

  • Pertuzumab IVDrug

    Pertuzumab is given as a fixed dose of 840 mg intravenous (IV) loading dose and then 420 mg IV for subsequent maintenance doses once every 3 weeks.

  • Trastuzumab IVDrug

    Trastuzumab is given as an 8 milligram per kilogram (mg/kg) intravenous (IV) loading dose and then 6 mg/kg IV for subsequent maintenance doses once every 3 weeks.

  • Trastuzumab EmtansineDrug

    Trastuzumab emtansine will be given at a dose of 3.6 mg/kg by intravenous (IV) infusion, once every 3 weeks.

  • Investigator's Choice of ChemotherapyDrug

    Option 1: Docetaxel and carboplatin once every 3 weeks for 6 cycles; Option 2: Doxorubicin plus cyclophosphamide once every 3 weeks for 4 cycles, followed by a taxane (docetaxel once every 3 weeks for 4 cycles or paclitaxel once every week for 12 cycles); Option 3: Dose-dense doxorubicin plus cyclophosphamide (ddAC) once every 2 weeks for 4 cycles, followed by a taxane (docetaxel once every 3 weeks for 4 cycles or paclitaxel once every week for 12 cycles).

  • SurgeryProcedure

    After completing their neoadjuvant therapy, participants will undergo surgical resection for early or locally advanced HER2+ breast cancer (if eligible for surgery). Participants may undergo breast-conserving surgery or mastectomy according to routine clinical practice. The surgery cannot be performed ≤2 weeks from the last systemic neoadjuvant therapy and must be performed ≤6 weeks after the last systemic neoadjuvant therapy.

  • RadiotherapyRadiation

    After surgery, radiotherapy is to be given as clinically indicated and as per local practice or institutional standards. The selected radiotherapy regimen should be initiated within 4 weeks after surgery.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cross-over Period: Percentage of Participants Who Preferred the Administration of PH FDC SC in the Home Setting Compared With the Hospital Setting in Question 1 of the Patient Preference Questionnaire (PPQ)Time frame: Upon completion of adjuvant cross-over period (Day 1 of Cycle 8 or 9; Cycle length = 21 days)

Locations

45 sites in 17 countries. Site status is shown where the registry gives one.

  • Centro Oncologico Korben

    Ciudad Autonoma Buenos Aires, Argentina

  • Centro de Investigaciones Médicas y Desarrollo LC S.R.L

    Buenos Aires, Ciudad Autónoma de BuenosAires, Argentina

  • University Clinical Center of the Republic of Srpska

    Banja Luka, Bosnia and Herzegovina

  • Cantonal Hospital Zenica

    Zenica, Bosnia and Herzegovina

  • Crio - Centro Regional Integrado de Oncologia

    Fortaleza, Ceará, Brazil

  • Hospital Araujo Jorge

    Goiânia, Goiás, Brazil

  • Hospital Nossa Senhora da Conceicao

    Porto Alegre, Rio Grande do Sul, Brazil

  • Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda

    São Paulo, São Paulo, Brazil

  • Multiprofile Hospital for Active Treatment Uni Hospital

    Panagyurishte, Bulgaria

  • Complex Oncology Center - Plovdiv First Internal Chemotherapy Department

    Plovdiv, Bulgaria

  • MHAT Nadezhda

    Sofia, Bulgaria

  • Royal Victoria Regional Health Centre

    Barrie, Ontario, Canada

  • Lakeridge Health Oshawa

    Oshawa, Ontario, Canada

  • North York General Hospital

    Toronto, Ontario, Canada

  • Jewish General Hospital

    Montreal, Quebec, Canada

  • Hopital du Saint Sacrement

    Québec, Quebec, Canada

  • Clinica Vespucio

    Santiago, Chile

  • Centro de Estudios Clínicos SAGA

    Santiago, Chile

  • Clinica CIMCA

    San José, Costa Rica

  • ICIMED Instituto de Investigación en Ciencias Médicas

    San José, Costa Rica

  • Hospital Metropolitano (Sede Lindora-Santa Ana)

    San José, Costa Rica

  • Clinical Hospital Centre Zagreb

    Zagreb, Croatia

  • Saifee Hospital

    Mumbai, Maharashtra, India

  • TATA Medical Centre

    Kolkata, West Bengal, India

  • International Cancer Institute (ICI)

    Eldoret, Kenya

  • The Aga Khan University-Kenya.

    Nairobi, Kenya

  • Iem-Fucam

    D.F., Mexico City, Mexico

  • Health Pharma Professional Research

    Mexico City, Mexico City, Mexico

  • Oncologico Potosino

    San Luis Potosí City, San Luis Potosí, Mexico

  • Instituto Regional de Enfermedades Neoplásicas del Sur

    Arequipa, Peru

  • Oncocenter Peru S.A.C.

    Lima, Peru

  • National Cancer Centre

    Singapore, Singapore

  • Tan Tock Seng Hospital

    Singapore, Singapore

  • Medical Oncology Centre of Rosebank

    Johannesburg, South Africa

  • Wilgers Oncology Centre

    Pretoria, South Africa

  • Korea University Anam Hospital

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico

    Jaén, Spain

  • Hospital Universitario Virgen de Arrixaca

    Murcia, Spain

  • Hospital Clinico Universitario de Salamanca

    Salamanca, Spain

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.